

8 February 2022

Drugs Used In Dermatology And Rheumatology In September 2021

Q1. How many patients were treated in September 2021 (or latest available month) by the dermatology department with the following drugs:

- **Abrocitinib (Cibinqo) 0**
- **Baricitinib (Olumiant) <5**
- **Bimekizumab (Bimzelx) 0**
- **Brodalumab (Kyntheum) <5**
- **Dupilumab (Dupixent) 82**
- **Ixekizumab (Taltz) 43**
- **Risankizumab (Skyrizi) 50**
- **Guselkumab (Tremfya) 86**
- **Secukinumab (Cosentyx) 41**
- **Tildrakizumab (Ilumetri) 7**
- **Tralokinumab (Adtralza) 0**
- **Ustekinumab (Stelara) 84**

Q2. How many patients were treated in September 2021 (or latest available month) by the rheumatology department with the following drugs:

- **Baricitinib (Olumiant) 60**
- **Filgotinib (Jyseleca) 0**
- **Guselkumab (Tremfya) 0**
- **Ixekizumab (Taltz) 65**
- **Secukinumab (Cosentyx) 214**
- **Tofacitinib (Xeljanz) 37**
- **Upadacitinib (Rinvoq) 40**
- **Ustekinumab (Stelara) 18**